Audible. Prime Member exclusive offer. First 3 months free, $14.95 a month after 3 months. Cancel anytime. Offer ends July 31, 2024, 11:59 PM PT. Get this deal

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment
Jul 15 2024
Length: 9 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to Cart failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Please try again

Unfollow podcast failed

Please try again

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Listen for free

View show details

Summary
Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab.

Show more Show less

Physical Illness & Disease Hygiene & Healthy Living Biological Sciences

Show more Show less

What listeners say about Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon